⌘K
t
CRISM Therapeutics Corporation announced that on 3 June 2024, Non-Executive Director Gerald Beaney purchased 25,000 ordinary shares at a price of 9.265 pence per share. Following this transaction, Mr. Beaney holds 25,000 ordinary shares, representing approximately 0.08% of the Company's total issued share capital.
| Date | 3 Jun 2024 |
| Time | 15:25:32 |
| Category | Director/PDMR dealings |
| ID | 9176Q |
3 June 2024
CRISM Therapeutics Corporation
(AIM:CRTX)
Director Dealing
CRISM Therapeutics Corporation ("CRISM" or the "Company") announces that it has been notified that Non-Executive Director, Gerald Beaney has purchased 25,000 ordinary shares of the Company at a price of 9.265 pence per share.
Following this purchase, Mr Beaney holds 25,000 ordinary shares, which represents approximately 0.08% of the Company's total issued share capital of 32,678,312.
Enquiries:
|
Company |
Nomad and Broker |
Financial PR |
|
CRISM Therapeutics Corporation |
S.P. Angel Corporate Finance LLP |
Buchanan |
|
Andrew Webb, CEO Chris McConville, CSO |
Richard Morrison Adam Cowl |
Mark Court mark.court@buchanancomms.co.uk Jamie Hooper jamie.hooper@buchanancomms.co.uk |
|
via Buchanan |
+44 (0) 20 3470 0470 |
+44 (0) 20 7466 5000 |
Dealings by Persons Discharging Managerial Responsibilities
|
1
|
Details of the person discharging managerial responsibilities / person closely associated
|
||||||||||
|
a)
|
Name |
Gerald Beaney |
|||||||||
|
2
|
Reason for the notification
|
||||||||||
|
a)
|
Position/status |
Non-Executive Director |
|||||||||
|
b)
|
Initial notification /Amendment |
Initial Notification |
|||||||||
|
3
|
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||||||||
|
a)
|
Name |
CRISM Therapeutics Corporation |
|||||||||
|
b)
|
LEI
|
213800XFW6MKVCHHPW88
|
|||||||||
|
4
|
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||||||||
|
a)
|
Description of the financial instrument, type of instrument |
Ordinary shares with no par value |
|||||||||
|
|
|
||||||||||
|
Identification code |
ISIN: VGG042401262
|
||||||||||
|
|
|
||||||||||
|
b)
|
Nature of the transaction
|
Purchase of shares |
|||||||||
|
c)
|
Price(s) and volume(s) |
|
|
|
|
||||||
|
d)
|
Aggregated information |
|
|||||||||
|
|
|
||||||||||
|
- Aggregated volume |
25,000 |
||||||||||
|
|
|
||||||||||
|
- Price |
£2,316.25 |
||||||||||
|
|
|
||||||||||
|
e)
|
Date of the transaction |
3 June 2024 |
|||||||||
|
f)
|
Place of the transaction |
Outside a trading venue |
|||||||||